α(1,2)fucosylation in human colorectal carcinoma

Muinelo-Romay,L.; Gil-Martín,E.; Fernández-Briera,A.

doi:10.3892/ol_00000064

α(1,2)fucosylation in human colorectal carcinoma

Authors:
- L. Muinelo-Romay
- E. Gil-Martín
- A. Fernández-Briera
View Affiliations

Affiliations: Department of Biochemistry, Genetics and Immunology, Faculty of Biology, University of Vigo, 36310 Vigo, Spain
Published online on: March 1, 2010 https://doi.org/10.3892/ol_00000064
Pages: 361-366

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lewisb and Lewisy (Le) antigens are known to be elevated in colorectal tumours. Alterations in the catalytic behaviour of GDP-L-fucose:β-D-galactoside α(1,2)fucosyltransferase [α(1,2)FT, EC: 2.4.1.69], the key enzyme in their synthesis, have been suggested as being responsible for these changes. In particular, an aberrant tumour-specific α(1,2)FT activity that converts Lea and Lex to Leb and Ley determinants, respectively, has been reported in colorectal cancer tissues. To clarify the catalytic function of this enzyme during colorectal tumorigenesis, we analyzed α(1,2)FT activity levels in healthy and tumour colon specimens using different acceptor substrates and determined the kinetic properties of the enzyme. To complete the study, the aberrant Lea/Lex α(1,2)fucosylation was determined in healthy and tumour colorectal tissues. A correlation analysis between the activity levels and various standard clinicopathological features, such as tumour stage, was also carried out to elucidate the role of these activities in tumour progression. The results obtained confirm the enhanced α(1,2)fucosylation in colorectal neoplastic tissues and the importance of the aberrant Lea/Lex α(1,2)FT activity in this increase. However, taking into account the high levels of Lea/Lex fucosylation observed in healthy control tissues, we must rule out the idea of a colorectal tumour-specific α(1,2)FT. On the other hand, no significant association was observed between α(1,2)FT activity levels and the clinicopathological characteristics. Overall, our results suggest that α(1,2)FT activity plays a critical role in the accumulation of Leb and Ley antigens in human colorectal carcinoma.

View Figures

View References

1	Hakomori SL: Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 56:5309–5318. 1996.PubMed/NCBI
2	Itzkowitz SH: Carbohydrate change in colon carcinoma. Acta Pathol Immunol Microbiol Scand. 100:173–180. 1992.
3	Miyake M and Hakomori SI: A specific cell surface glycoconjugate controlling cell motility: evidence by functional monoclonal antibodies that inhibit cell motility and tumor metastasis. Biochemistry. 30:3328–3334. 1991. View Article : Google Scholar : PubMed/NCBI
4	Le Pendu J, Marionneau S, Cailleau-Thomas A, Rocher J, Le Moullac-Vaidye B and Clément M: ABH and Lewis Histo-blood group antigens in cancer. APMIS. 109:9–31. 2001.
5	Naitoh H, Nakajima T, Nagamachi Y and Yazawa S: A clinicopathological evaluation of anti-fucosylated antigen antibody (YB-2) in colorectal carcinoma. Glycosylation Dis. 1:31–36. 1994. View Article : Google Scholar
6	Ørntof TF, Geenwell P, Clausen H and Watkins WM: Regulation of the oncodevelopmental expression of type 1 chain ABH and Lewis(b) blood group antigens in human colon by alpha-2-L-fucosylation. Gut. 32:287–293. 1991.PubMed/NCBI
7	Yazawa S, Nishimura T, Ide M, Asao T, Okamura A, Tanaka S, Takai I, Yagihashi Y, Saniabadi AR and Kochibe N: Tumor-related expression of α1,2fucosylated antigens on colorectal carcinoma cells and its suppression by cell-mediated priming using sugar acceptors for α1,2fucosyltransferase. Glycobiology. 12:545–553. 2002.
8	Sun J, Thurin J, Cooper HS, Wang P, Mackiewicz M, Steplewski Z and Blaszyk-Thurin M: Elevated expression of H-type GDP-L-fucose:β-D-galactoside α-2-L-fucosyltransferase is associated with human colon-adenocarcinoma progression. Proc Natl Acad Sci USA. 92:5724–5728. 1995.PubMed/NCBI
9	Larsen RD, Ernst LK, Nair RP and Lowe JB: Molecular cloning sequence and expression of human GDP-L-fucose:β-D-galactoside 2-α-L-fucosyltransferase cDNA that can form the H group antigen. Proc Natl Acad Sci USA. 87:6674–6678. 1990.
10	Rouquier S, Lowe JB, Kelly RJ, Fertitta AL, Lennon GG and Giordi G: Molecular cloning of a human genomic region containing the H blood group α(1,2)fucosyltransferase gene and two H locus-related DNA restriction fragments. Isolation of a candidate for the human secretor blood group locus. J Biol Chem. 270:4632–4639. 1995.PubMed/NCBI
11	Kelly RJ, Rouquier S, Giordi G, Lennon GG and Lowe JB: Sequence and expression of a candidate for the human secretor blood group α(1,2)fucosyltransferase gene (FUT2). Homozygosity for an enzyme-inactivating nonsense mutation commonly correlates with the non-secretor phenotype. J Biol Chem. 270:4640–4649. 1995.
12	Avent ND: Human erythrocyte antigen expression: its molecular basis. Br J Biomed Sci. 54:16–37. 1997.PubMed/NCBI
13	Sarnesto A, Köhlin T, Hindsgaul O, Thurin J and Blaszczyk-Thurin M: Purification of the secretor-type β-galactoside α1→2fucosyltransferase from human serum. J Biol Chem. 265:15067–15075. 1990.
14	Yazawa S, Nakamura J, Asao T, Nagamachi Y, Sagi M, Matta KL, Tachikawa T and Akamatsu M: Aberrant α1→2fucosyltransferase found in human colorectal carcinoma involved in the accumulation of Le^b and Y antigens in colorectal tumors. Jpn J Cancer Res. 84:989–995. 1993.
15	Sakamoto J, Furukawa K, Gordon-Cardo C, Yin B, Retting W, Oettgen H, Old L and Lloyd K: Expression of Lewis^a, Lewis^b, X and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines. Cancer Res. 46:1553–1561. 1986.
16	Muinelo-Romay L, Vázquez-Martín C, Villar-Portela S, Cuevas E, Gil-Martín E and Fernández-Briera A: Expression and enzyme activity of α(1,6)fucosyltransferase in human colorectal cancer. Int J Cancer. 123:641–646. 2008.
17	Mejías-Luque R, López-Ferrer A, Garrido M, Fabra A and de Bolós C: Changes in the invasive and metastatic capacities of HT-29/M3 cells induced by the expression of fucosyltransferase 1. Cancer Sci. 98:1000–1005. 2007.PubMed/NCBI
18	Kim Y and Itzkowitz SH: Carbohydrate antigen expression in adenocarcinoma sequence. Prog Clin Biol Res. 279:241–250. 1988.
19	Blaszczyc-Thurin M, Sarnesto A, Thurin J, Hindsgaul O and Koprowski H: Biosynthetic pathway for the Le^b and Y glycolipids in the gastric carcinoma cell line Kato III as analyzed by a novel assay. Biochem Biophys Res Commun. 151:100–108. 1988.
20	Goupille C, Marionneau S, Bureau V, Hallouin F, Meichenin M, Rocher J and Le Pendu J: α(1,2)fucosyltransferase increases resistance to apoptosis of rat colon carcinoma cells. Glycobiology. 10:375–382. 2000.
21	Hallouin F, Goupille C, Bureau V, Meflash K and Le Pendu J: Increased tumorigenicity of rat colon carcinoma cells after α(1,2)fucosyltransferase FTA anti-sense cDNA transfection. Int J Cancer. 80:601–611. 1999.
22	Nishihara S, Hiraga T, Ikehara Y, Kudo T, Iwasaki H, Morozumi K, Akamatsu S, Tachikawa T and Narimatsu H: Molecular mechanisms of expression of Le^b antigen and other type I Lewis antigens in human colorectal cancer. Glycobiology. 9:607–616. 1999.
23	Ravn V and Dabelsteen E: Tissue distribution of histo-blood group antigens. APMIS. 108:1–28. 2000. View Article : Google Scholar : PubMed/NCBI
24	Itzkowitz SH, Rajvir D, Byrd JC and Kim YS: Blood group antigen synthesis and degradation in normal and cancerous colonic tissues. Gastroenterology. 99:431–442. 1990.PubMed/NCBI
25	Chandrasekaran EV, Jain RK and Matta KL: Expression of blood group Lewis b determinant from Lewis a: association of this novel α(1,2)-L-fucosylating activity with the Lewis type α(1,3/4)-L-fucosyltransferase. Biochemistry. 34:4748–4756. 1995.PubMed/NCBI
26	Ichikawa D, Handa K, Withers DA and Hakomori S: Histo-blood group A/B versus H status of human carcinoma cells as correlated with haptotactic cell motility: approach with A and B gene transfection. Cancer Res. 57:3092–3996. 1997.PubMed/NCBI
27	Tsuboi K, Asao T, Ide M, Hashimoto S, Noguchi K, Kominato Y, Saniabadi AR, Kuwano H and Yazawa S: α(1,2)fucosylation is a superior predictor of postoperative prognosis for colorectal cancer compared with blood group A, B, or sialyl Lewis X antigen generated within colorectal tumor tissues. Ann Surg Oncol. 14:1880–1889. 2007.
28	Moehler TM, Sauer S, Witzel M, Andrulis M, Garcia-Vallejo JJ, Grobholz R, Willhauck-Fleckenstein M, Greiner A, Goldschmidt H and Schwartz-Albiez R: Involvement of α1–2-fucosyltransferase I (FUT1) and surface-expressed Lewis(y) (CD174) in first endothelial cell-cell contacts during angiogenesis. J Cell Physiol. 215:27–36. 2008.
29	Russell L, Waring P and Beaver JP: Increased cell surface exposure of fucose residues in a late event in apoptosis. Biochem Biophys Res Commun. 250:449–453. 1996. View Article : Google Scholar : PubMed/NCBI
30	Kannagi R: Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer. Glycoconj J. 14:577–584. 1997. View Article : Google Scholar : PubMed/NCBI